Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
17.03
Dollar change
-0.88
Percentage change
-4.91
%
IndexRUT P/E- EPS (ttm)-1.66 Insider Own18.86% Shs Outstand47.82M Perf Week0.29%
Market Cap729.74M Forward P/E- EPS next Y-2.09 Insider Trans-0.54% Shs Float34.77M Perf Month-15.86%
Income-67.67M PEG- EPS next Q-0.48 Inst Own96.32% Short Float24.45% Perf Quarter-20.83%
Sales0.00M P/S- EPS this Y-15.09% Inst Trans-19.26% Short Ratio8.96 Perf Half Y3.21%
Book/sh4.94 P/B3.45 EPS next Y-10.08% ROA-36.52% Short Interest8.50M Perf Year110.77%
Cash/sh5.63 P/C3.02 EPS next 5Y- ROE-39.72% 52W Range7.69 - 26.35 Perf YTD-24.98%
Dividend Est.- P/FCF- EPS past 5Y-26.63% ROI-28.48% 52W High-35.37% Beta2.40
Dividend TTM- Quick Ratio15.29 Sales past 5Y0.00% Gross Margin- 52W Low121.46% ATR (14)1.21
Dividend Ex-Date- Current Ratio15.29 EPS Y/Y TTM8.69% Oper. Margin0.00% RSI (14)40.27 Volatility7.03% 6.75%
Employees103 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price34.11
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q11.80% Payout- Rel Volume1.06 Prev Close17.91
Sales Surprise- EPS Surprise-17.14% Sales Q/Q- EarningsMar 21 BMO Avg Volume948.58K Price17.03
SMA20-2.72% SMA50-17.40% SMA200-0.87% Trades Volume1,005,155 Change-4.91%
Date Action Analyst Rating Change Price Target Change
Feb-05-24Initiated Jefferies Buy $36
Nov-29-23Initiated William Blair Outperform $38
Oct-24-23Initiated Cantor Fitzgerald Overweight $40
Oct-19-23Initiated Stifel Buy $31
Sep-05-23Initiated Citigroup Buy $22
Jul-18-23Initiated Guggenheim Buy $34
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $3 → $16
Aug-30-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $3
Dec-08-21Initiated Wells Fargo Overweight $17
Oct-19-21Resumed Morgan Stanley Overweight $20
Mar-23-24 05:31AM
Mar-21-24 01:53PM
07:00AM
Mar-20-24 07:00AM
Mar-08-24 08:50AM
10:11AM Loading…
Feb-27-24 10:11AM
08:00AM
Feb-01-24 04:30PM
Jan-31-24 08:00AM
Jan-08-24 07:00AM
Jan-02-24 08:00AM
Dec-18-23 08:49PM
Nov-28-23 04:30PM
Nov-09-23 08:10AM
07:00AM
08:15AM Loading…
Nov-06-23 08:15AM
07:00AM
Oct-30-23 08:00AM
Oct-09-23 09:40AM
Oct-02-23 09:14AM
07:00AM
Oct-01-23 11:00AM
Sep-25-23 08:50AM
Sep-19-23 08:00AM
Sep-01-23 02:00PM
11:30AM
Aug-31-23 09:55AM
08:30AM
Aug-30-23 08:00AM
Aug-25-23 10:13AM
08:50AM Loading…
Aug-23-23 08:50AM
Aug-22-23 08:00AM
Aug-15-23 01:46PM
Aug-10-23 07:00AM
Aug-01-23 10:00AM
Jul-24-23 08:00AM
Jul-18-23 02:58PM
Jun-20-23 08:00AM
Jun-08-23 11:14AM
May-31-23 08:00AM
May-24-23 07:33AM
May-22-23 04:30PM
May-17-23 10:16PM
04:01PM
May-16-23 07:00AM
May-11-23 08:39AM
07:00AM
May-02-23 04:35PM
May-01-23 07:00AM
Apr-25-23 01:07PM
08:00AM
Apr-13-23 04:30PM
Mar-31-23 07:00AM
Mar-16-23 07:00AM
Mar-14-23 07:14AM
Feb-28-23 08:00AM
Feb-19-23 10:53AM
Feb-17-23 06:43PM
Feb-06-23 12:00PM
Jan-31-23 09:40AM
Jan-09-23 07:00AM
Jan-05-23 08:00AM
Jan-03-23 05:40AM
Dec-30-22 09:03AM
Dec-23-22 09:40AM
Dec-13-22 11:41AM
Dec-12-22 01:37PM
Dec-08-22 07:00AM
Dec-07-22 09:55AM
Nov-22-22 08:00AM
Nov-16-22 11:26AM
Nov-10-22 07:00AM
Oct-11-22 10:06AM
07:00AM
Oct-06-22 08:00AM
Oct-05-22 06:26AM
Sep-26-22 08:00AM
Sep-10-22 07:00AM
Sep-06-22 08:00AM
Aug-29-22 01:58PM
Aug-11-22 07:00AM
Jun-09-22 12:00PM
May-25-22 03:10PM
May-18-22 12:49PM
07:00AM
May-17-22 08:00AM
May-12-22 07:00AM
May-02-22 04:30PM
Apr-15-22 08:03AM
Apr-06-22 08:00AM
Mar-17-22 07:00AM
Mar-04-22 02:34PM
Mar-01-22 08:00AM
Feb-28-22 08:00AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 10:00AM
Jan-03-22 08:00AM
Dec-14-21 07:00AM
Nov-09-21 04:30PM
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder GwendolynSee RemarksJan 19 '24Option Exercise1.0111,00011,11031,000Jan 19 06:30 PM
Binder GwendolynSee RemarksJan 19 '24Sale19.5911,000215,43920,000Jan 19 06:30 PM
Binder GwendolynSee RemarksDec 19 '23Option Exercise1.0111,00011,11031,000Dec 19 08:37 PM
Binder GwendolynSee RemarksDec 19 '23Sale21.8911,000240,78920,000Dec 19 08:37 PM
Binder GwendolynSee RemarksNov 20 '23Option Exercise1.0111,00011,11031,000Nov 21 04:30 PM
Binder GwendolynSee RemarksNov 20 '23Sale17.8211,000196,01420,000Nov 21 04:30 PM
Binder GwendolynSee RemarksOct 19 '23Option Exercise1.0111,00011,11031,000Oct 19 07:40 PM
Binder GwendolynSee RemarksOct 19 '23Sale13.3611,000146,92120,000Oct 19 07:40 PM
Binder GwendolynSee RemarksSep 19 '23Option Exercise1.0111,00011,11031,000Sep 20 04:30 PM
Binder GwendolynSee RemarksSep 19 '23Sale17.5711,000193,22020,000Sep 20 04:30 PM
Binder GwendolynSee RemarksAug 21 '23Option Exercise1.0111,00011,11031,000Aug 22 04:30 PM
Binder GwendolynSee RemarksAug 21 '23Sale13.4211,000147,58320,000Aug 22 04:30 PM
Binder GwendolynSee RemarksJul 19 '23Option Exercise1.0111,00011,11031,000Jul 19 08:37 PM
Binder GwendolynSee RemarksJul 19 '23Sale13.8211,000152,02220,000Jul 19 08:37 PM
Binder GwendolynSee RemarksJun 20 '23Option Exercise1.0111,00011,11031,000Jun 21 04:38 PM
Binder GwendolynSee RemarksJun 20 '23Sale12.9911,000142,92520,000Jun 21 04:38 PM
Binder GwendolynSee RemarksMay 19 '23Option Exercise1.0122,00022,22042,000May 19 08:10 PM
Binder GwendolynSee RemarksMay 19 '23Sale11.8122,000259,83320,000May 19 08:10 PM